FIGURE 2.

OAd-MSC TLR4^−/− improves the antitumor efficacy of OAd-MSC WT in vivo. A, Schematic illustration of in vivo experimental design. B, Graph on the left represents the individual AUC of mice treated with PBS (black), OAd-MSC WT (blue), or OAd-MSC TLR4^−/− (red). Graph on the right represents the AUC of treated groups expressed as mean + SEM (n = 17–25). Follow-up of tumor growth in mice treated with PBS (black, n = 35), OAd-MSC WT (blue, n = 20), or OAd-MSC TLR4^−/− (red, n = 20) represented as mean + SEM (C) and individual values (D). E, Antitumor activity of OAd-MSC WT and OAd-MSC TLR4^−/− in relation to control group (n = 20). Unpaired t test. F, Tumor growth of mice treated with PBS, OAd-MSC WT or OAd-MSC TLR4^−/− at indicated days. One-way ANOVA followed by Tukey multiple comparisons tests. G, Tumor weight of treated mice at endpoint (n = 15–16). One-way ANOVA followed by Tukey multiple comparisons tests. H, Representative images of IHC of CD45⁺ cells in treated tumors (n = 3–5). I, Density of tumor-infiltrating leukocytes, NK cells, and T cells at endpoint expressed as percentage per cm³ of tumor, as well as the CD4⁺/CD8⁺ ratio (n = 5–9). J, Density of tumor-infiltrating innate immune populations and ratio of proinflammatory/anti-inflammatory status of macrophages (M1/M2 ratio). One-way ANOVA followed by Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.